Internal Medicine, Hematology & Oncology · Boston, MA
NPI
1942418900
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
3
Medicare group memberships
Hospitals
3
Hospital affiliations
330 Brookline Ave, Shapiro 9
Boston, MA, 02215
Phone (617) 667-2131
Groups this clinician bills Medicare through
Medicare paid, 2024
$25K
267 services
Medicare patients, 2024
74
Average age 75
Drug cost, 2024
$1.4M
192 prescriptions
Company payments, 2025
$2,030
From 6 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Daniel B Costa was code 99215 (office e&m - established), 138 times for 42 patients. In total Daniel B Costa billed 267 services in 15 codes, and Medicare paid $25K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Facility | 138 | 42 | $113.94 | $16K |
| 99233 Hospital E&M - Subsequent | Facility | 31 | 12 | $98.83 | $3,064 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 20 | 16 | $13.82 | $276 |
| 99205 Office E&M - New | Facility | 11 | 11 | $151.69 | $1,669 |
By year: 2022 $29K for 273 services; 2023 $32K for 317 services; 2024 $25K for 267 services.
Medicare prescription drug claims, 2024
In 2024, the drug Daniel B Costa prescribed most often to Medicare patients was Tagrisso (Osimertinib Mesylate), with 61 prescriptions and refills. In total Daniel B Costa wrote 192 Medicare prescriptions that cost $1.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tagrisso Osimertinib Mesylate | 61 | 61 | Under 11 | $733K |
| Gilotrif Afatinib Dimaleate | 23 | 23 | Under 11 | $242K |
| Eliquis Apixaban | 20 | 22 | Under 11 | $12K |
| Erlotinib Hcl Generic | 13 | 13 | Under 11 | $1,062 |
| Tepmetko Tepotinib Hcl | 12 | 12 | Under 11 | $275K |
| Alecensa Alectinib Hcl | 11 | 11 | Under 11 | $103K |
| Dexamethasone Generic | 11 | 11 | Under 11 | $67.93 |
Brand drugs: 128 claims; generic drugs: 64 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Daniel B Costa $2,030 ($2,030 in general payments such as food, travel and fees) from 6 companies. The largest payer was Boehringer Ingelheim Pharmaceuticals, Inc. with $2,030.
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $2,030 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.